PHH Stock Price, News & Analysis

Park Ha Biological Technology Co., Ltd., historically trading on the Nasdaq Capital Market under the ticker symbol PHH, is a consumer-focused company in the household and personal products industry within the broader consumer defensive sector. According to its public offering materials, the company is primarily engaged in developing its own private skincare label, direct skincare product sales, and franchise alliance promotions under its proprietary brand "Park Ha." The business emphasizes cost-effective approaches to addressing skin problems and aims to enhance the confidence of women who seek skin treatment solutions.

Established in 2016, Park Ha Biological Technology Co., Ltd. has built a retail and franchise network in China centered on its skincare offerings. As described in its offering documents, the company operates a combination of directly owned and franchised stores that use the "Park Ha" and "Geni" store names. This structure allows the company to promote its proprietary skincare label through both self-operated outlets and franchise alliances that carry and promote its products.

In connection with its initial public offering of ordinary shares, Park Ha Biological Technology Co., Ltd. outlined plans to use capital raised from investors to expand the scale of its directly owned stores in the People’s Republic of China, to purchase existing product patents in order to develop proprietary products, and to acquire ingredient suppliers with the goal of reducing long-term production costs. These stated uses of proceeds highlight a focus on deepening control over product development and supply, while also growing its physical retail footprint.

As part of its value-added services associated with its skincare products, the company offers what it describes as a "light beauty experience." This is characterized as a quick, complimentary after-sales beauty service performed in both directly operated stores and franchise locations. The service is positioned as an enhancement to the product offering and is intended to support customers after purchase within the company’s store network.

Park Ha Biological Technology Co., Ltd. is organized as a foreign private issuer and has filed reports with the U.S. Securities and Exchange Commission under the Exchange Act. The company has indicated that it files annual reports under cover of Form 20-F. Through these filings, it provides investors with information such as operating and financial review and prospects, as well as unaudited consolidated financial statements for specified periods.

In its corporate governance disclosures, the company has reported holding annual general meetings where shareholders vote on key corporate matters. For example, shareholders have considered and approved changes to the company’s share capital structure, including the establishment of a dual-class share capital with Class A ordinary shares and Class B ordinary shares, each with different voting rights per share. Shareholders have also approved amendments and restatements of the company’s memorandum and articles of association to reflect these changes, and have authorized the board to implement a share consolidation within a specified ratio range, with the exact ratio to be determined by the board.

Park Ha Biological Technology Co., Ltd. has also disclosed that its shareholders have ratified the appointment of an independent registered public accounting firm to audit the company’s consolidated financial statements for a specified fiscal year. These governance and audit-related decisions are documented in current reports furnished to the SEC on Form 6-K.

From a capital markets perspective, the company completed an initial public offering of ordinary shares on the Nasdaq Capital Market, with the ordinary shares beginning to trade under the symbol "PHH". The offering was conducted on a firm commitment basis, and the company described the total number of ordinary shares offered and the public offering price per share in its public announcements. It also noted that it had granted the underwriters an option to purchase additional ordinary shares at the public offering price, less underwriting discounts.

Subsequently, Park Ha Biological Technology Co., Ltd. announced that it would change its Nasdaq ticker symbol from "PHH" to "BYAH". The company stated that the change was intended to prevent potential confusion with a delisted company that had previously used the same symbol. The company indicated that the symbol change would become effective on a specified trading date and that its ordinary shares would continue to be listed on Nasdaq, with no action required by existing shareholders and no change to the CUSIP.

The company has also reported receiving notifications from the Nasdaq Stock Market regarding deficiencies in meeting certain continued listing standards, including the minimum closing bid price requirement and the minimum market value of listed securities requirement. These notifications did not constitute immediate delisting but provided compliance periods during which the company could seek to regain compliance, potentially through measures such as a reverse stock split, subject to meeting other listing standards. The company has stated its intention to monitor its market value and bid price and to consider available options to address these deficiencies, while acknowledging that there can be no assurance of regaining or maintaining compliance.

Park Ha Biological Technology Co., Ltd. has additionally disclosed changes in its board composition, including the resignation of an independent director, and has stated that such a resignation was not the result of any disagreement with the company’s operations, policies, or procedures. These changes are documented in the company’s current reports filed with the SEC.

Business focus and operations

Based on its public descriptions, Park Ha Biological Technology Co., Ltd. concentrates on the development and promotion of its proprietary skincare brand "Park Ha." Its activities include:

• Developing a private skincare label under the "Park Ha" brand.
• Engaging in direct skincare product sales.
• Promoting franchise alliances that operate stores under the "Park Ha" and "Geni" names in China.
• Providing a "light beauty experience" as a complimentary after-sales service in its directly operated and franchise stores.

The company’s stated commitment is to provide cost-effective solutions to skin problems and to improve the confidence of women who seek skin treatment, positioning its brand and services around this objective.

Capital structure and corporate actions

Through shareholder approvals documented in its SEC filings, Park Ha Biological Technology Co., Ltd. has implemented a dual-class share structure, with Class A ordinary shares and Class B ordinary shares having different voting rights per share. The company has also obtained shareholder approval for a potential share consolidation within a defined ratio range, with the effective date and exact ratio to be determined by the board and announced within a specified timeframe. These actions are intended to be reflected in the company’s amended and restated memorandum and articles of association.

The company’s communications also describe its engagement with Nasdaq’s listing requirements, including responses to notifications regarding minimum bid price and market value of listed securities. While these notifications do not immediately affect the listing or trading of its ordinary shares, they outline conditions and timelines for regaining compliance, as well as potential consequences if compliance is not achieved, including possible delisting and the right to appeal any such determination.

Historical ticker symbol context

For investors researching the symbol PHH, it is important to note that Park Ha Biological Technology Co., Ltd. announced a change of its Nasdaq trading symbol from "PHH" to "BYAH". The company has explicitly stated that the change is intended to avoid confusion with a previously delisted company that used the same symbol. As a result, historical references to "PHH" in the context of Nasdaq listings may relate to different entities at different times, and Park Ha Biological Technology Co., Ltd. has taken steps to distinguish its securities through the new "BYAH" symbol while maintaining its Nasdaq listing and CUSIP.